Krazati (adagrasib) — Highmark
locally advanced or metastatic colorectal cancer (CRC)
Initial criteria
- age ≥ 18 years
- diagnosis of locally advanced or metastatic CRC (ICD-10: C18, C19, C20, C21)
- disease is KRAS G12C-mutated as determined by an FDA-approved test
- Krazati is used in combination with cetuximab
- member has received prior treatment with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy
Reauthorization criteria
- prescriber attests that the member is tolerating therapy and has experienced a therapeutic response defined as disease improvement OR delayed disease progression
Approval duration
12 months